The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Analysis according to prognostic factors in patients (pts) treated with first-line bevacizumab (BEV) combined with paclitaxel (PAC) for HER2-negative metastatic breast cancer (mBC) in a routine oncology practice study.
Iris Schrader
No relevant relationships to disclose
Frank Gerhard Foerster
No relevant relationships to disclose
Andreas Schneeweiss
Consultant or Advisory Role - Roche
Honoraria - Roche
Matthias Geberth
No relevant relationships to disclose
Lars Hahn
No relevant relationships to disclose
Claudia Schumacher
No relevant relationships to disclose
Martin Michael Hertz-Eichenrode
No relevant relationships to disclose
Winfried Schoenegg
No relevant relationships to disclose
Matthias Kim Wolfgarten
Other Remuneration - Roche
Andreas Kutscheidt
No relevant relationships to disclose
Marcus Schmidt
Consultant or Advisory Role - Roche
Stock Ownership - Roche
Honoraria - Roche
Bahriye Aktas
No relevant relationships to disclose